Credit: St. Jude Biomedical Communications
Jeffrey Rubnitz, M.D., Ph.D., of St. Jude Children’s Research Hospital, led a study that adds to evidence that some pediatric AML patients may benefit from drugs designed to kill cells that carry a particular protein on their surface.